Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

Yi Lin,Lugui Qiu,Saad Usmani,Chng Wee Joo,Luciano Costa,Benjamin Derman,Juan Du,Hermann Einsele,Carlos Fernandez de Larrea,Roman Hajek,P Joy Ho,Efstathios Kastritis,Joaquin Martinez-Lopez,Maria-Victoria Mateos,Joseph Mikhael,Philippe Moreau,Chandramouli Nagarajan,Ajay Nooka,Michael O'Dwyer,Fredrik Schjesvold,Surbhi Sidana,Niels WCJ van de Donk,Katja Weisel,Sonja Zweegman,Noopur Raje,Paula Rodriguez Otero,Larry D Anderson,Shaji Kumar,Tom Martin
DOI: https://doi.org/10.1016/s1470-2045(24)00094-9
IF: 54.433
2024-05-31
The Lancet Oncology
Abstract:Summary Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
oncology
What problem does this paper attempt to address?